Latest Hematology Stories

NEW YORK, Aug. 1, 2012 /PRNewswire/ -- Go into New York City's Yankee Stadium on Saturday, August 4 and you will be greeted with a sight never seen before. The bleachers and seats of the stadium, usually filled with spectators sporting iconic blue and white fan gear, will present a sea of red. The New York Yankees, in partnership with DKMS, the world's largest bone marrow donor center, will distribute red caps to all the spectators who enter the stadium prior to the 1:05PM start...

FORT LEE, N.J., July 31, 2012 /PRNewswire/ -- Effective today, The Kedrion Group [www.kedrion.com] completed acquisition of the RhoGAM(®) line of products [www.RhoGAM.com] from Ortho-Clinical Diagnostics, Inc. (OCD). The acquisition includes the transfer of the Rho(D) Immune Globulin (Human) RhoGAM(®) Ultra-Filtered PLUS and Rho(D) Immune Globulin (Human) MICRhoGAM(®) Ultra-Filtered PLUS products as well as Somerset Laboratories, Inc., a wholly owned subsidiary of Ortho Clinical...

ST. PAUL, Minn., July 26, 2012 /PRNewswire-USNewswire/ -- July marks a major milestone for local nonprofit Memorial Blood Centers and Minnesota-based Donaldson Company (NYSE;DCI): a 40-year partnership that has promoted the cause of blood donation and helped save and sustain tens of thousands of lives in our local community. "As one of Minnesota's oldest and largest nonprofit community-based blood centers, Memorial Blood Centers has been extremely fortunate to have such a...

IRVINE, Calif., July 26, 2012 /PRNewswire/ -- According to a new study in the July 2012 print edition of Anesthesiology, blood transfusion, the most common procedure performed in U.S. hospitals(1), has wide variation in frequency by surgical procedure and physician as well as wide variation in the hemoglobin trigger used to help decide whether to transfuse.(2) The study also showed a significant number of transfusion decisions are made without laboratory hemoglobin measurements. The...

By: Katie Williams, Ivanhoe Health Correspondent (Ivanhoe Newswire) – Millions of patients affected by cardiovascular disease need small-diameter blood vessel grafts to help route their blood around blocked arteries. Now, researchers have created a new way to grow healthy, new small-diameter blood vessels from adult stem cells extracted during liposuction. These blood vessels are grown in a lab and could solve large problems associated with grafting blood vessels elsewhere in the...

WASHINGTON, July 25, 2012 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced its commitment of $9 million over a three-year period to provide funding, in the form of bridge grants, for its hematologists whose vital research will not be accomplished due to the severe funding reductions for biomedical research. ASH's new grant program was designed...

Researchers: Findings about innate peptide may offer new avenue of research for combating HIV, other viruses Human defensins, aptly named antimicrobial peptides, are made in immune system cells and epithelial cells (such as skin cells and cells that line the gut). One of these peptides, human neutrophil peptide 1, under certain circumstances hinders HIV infection, but exactly how it works remains unclear. HIV entry into mature T-helper cells (cells essential to the immune system)...

SOUTH SAN FRANCISCO, Calif., July 25, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Blood, the medical journal of the American Society of Hematology, has published results from the 003-A1 Phase 2b trial, a single-arm, multicenter clinical trial evaluating Kyprolis(TM) (carfilzomib) for Injection for the treatment of patients with advanced multiple myeloma, who had received a median of five prior anti-myeloma regimens. The lead author was Dr....

REHOVOT, Israel, July 24, 2012 /PRNewswire/ -- Biokine Therapeutics Ltd. announced today that it has received Orphan Drug designation from the US Food and Drug Administration (FDA) for the mobilization of hematopoietic stem cells from bone marrow into peripheral blood for collection and subsequent transplantation in patients with hematological cancers. Earlier in 2012, Biokine received FDA approval to conduct a Phase 2 clinical study for stem cell mobilization in Multiple...

CRESSKILL, N.J., July 24, 2012 /PRNewswire/ -- Bayer, the German chemical and pharmaceutical manufacturer, has settled another 1000 Yaz and Yasmin related lawsuits since the April report, raising the amount Bayer has agreed to pay out to $300 million. An additional 7,500 suits are expected to be settled by year's end according to the federally appointed mediator working on the cases (source). However, disbursement of settlement funds to plaintiffs and their attorneys may take months,...